Predict your next investment

Corporation
HEALTHCARE | Drug Development
corridorpharma.com

See what CB Insights has to offer

Total Raised

$20.71M

Investors Count

8

Deal Terms

1

Corridor Pharmaceuticals Funding, Corridor Pharmaceuticals Valuation & Corridor Pharmaceuticals Revenue

3 Fundings

Corridor Pharmaceuticals's latest funding round was a Debt for $1.55M on January 31, 2013.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/31/2013

Debt

$1.55M

$0.00B

((9.99x))

FY 1234

1

6/17/2010

Series A

$99M

$0.00B

((9.99x))

FY 1234

10

9/10/2009

Seed VC

$99M

$0.00B

((9.99x))

FY 1234

10

Date

1/31/2013

6/17/2010

9/10/2009

Round

Debt

Series A

Seed VC

Amount

$1.55M

$99M

$99M

Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

Corridor Pharmaceuticals Deal Terms

1 Deal Term

Corridor Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from June 17, 2010.

Round

Series A

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

Corridor Pharmaceuticals Investors

8 Investors

Corridor Pharmaceuticals has 8 investors. Domain Associates invested in Corridor Pharmaceuticals's Debt funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

6/17/2010

1/31/2013

2
Series A, Debt (2013)

Venture Capital

New Jersey

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

Maryland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Pennsylvania

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Maryland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

Maryland

First funding

6/17/2010

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

1/31/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

2
Series A, Debt (2013)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Corporate Venture

Venture Capital

Venture Capital

Corporation

Location

New Jersey

Maryland

Pennsylvania

Maryland

Maryland

Corridor Pharmaceuticals Acquisitions

2 Acquisitions

Corridor Pharmaceuticals acquired 2 companies. Their latest acquisition was Arginetix on June 17, 2010.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/17/2010

Series A - II

$10.75M

Merger

1

6/17/2010

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/17/2010

6/17/2010

Investment Stage

Series A - II

Series A - II

Companies

Subscribe to see more

Valuation

Total Funding

$10.75M

$99M

Note

Merger

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.